MedTrace Logo

Study With Atu027 in Patients With Advanced Solid Cancer

NCT00938574 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2013-04-09

No results posted yet for this study

Summary

This is a phase I, prospective, open-label, single center, dose finding study with Atu027 (an siRNA formulation) given as single treatment followed by repeated treatment (repeated treatment phase: 8 treatments within 4 weeks) as therapy in subjects with advanced solid cancer.

Conditions

Interventions

DRUG

Atu027

Sponsors & Collaborators

  • Silence Therapeutics GmbH

    lead INDUSTRY

Principal Investigators

  • Dirk Strumberg,, MD, Prof., Director · Dept. of Hematology & Med. Oncology, Univ. of Bochum, Marienhospital Herne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-07-31
Completion
2012-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938574 on ClinicalTrials.gov